Single center, double blind, randomised, placebo-controlled study investigating Ampakine CX1739 in patients with mild-to-moderate obstructive sleep apnoea.
Phase of Trial: Phase II
Latest Information Update: 08 Jan 2018
At a glance
- Drugs CX 1739 (Primary)
- Indications Sleep apnoea syndrome
- Focus Adverse reactions
- 08 Jan 2018 According to a RespireRx Pharmaceuticals media release, data from this trial will be presented at The Biotech Showcase 2018.
- 03 Feb 2011 Results have been reported in a Cortex Pharmaceuticals media release.
- 03 Feb 2011 New trial record